{
    "nctId": "NCT00820690",
    "briefTitle": "Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer",
    "officialTitle": "Gene Expression Signature and Immunohistochemical Markers Associated With Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 80,
    "primaryOutcomeMeasure": "Clinical objective and pathological responses to chemotherapy",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women with locally advanced women breast cancer\n* Histology: ductal ou lobular invasive histology\n* Agreement to take part in the study and signature of the informed consent\n* Clinical condition to receive doxorubicin/cyclophosphamide and paclitaxel\n* ECOG 0 or I\n\nExclusion Criteria:\n\n* Not clinical stage III\n* Inflammatory breast cancer\n* Previous treatment\n* Previous diagnosis of cancer (except basal cell or squamous cell skin carcinoma and non-invasive cervical carcinoma)\n* Pregnancy\n* Absence of clinical condition to receive chemotherapy",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}